Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

David G. Strauss, Gary Gintant, Zhihua Li, Wendy Wu, Ksenia Blinova, Jose Vicente, J. Rick Turner, Philip T. Sager

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA-sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring together scientists, clinicians, and regulators from multiple geographic regions to evaluate progress to date in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative, a new paradigm to evaluate proarrhythmic risk. Study reports from the 4 different components of the CiPA paradigm (ionic current studies, in silico modeling to generate a Torsade Metric Score, human induced pluripotent stem cell–derived ventricular cardiomyocytes, and clinical ECG assessments including J-Tpeakc) were presented and discussed. This paper provides a high-level summary of the CiPA data presented at the meeting.

Original languageEnglish (US)
JournalTherapeutic Innovation and Regulatory Science
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Environmental Health
Safety
Research
Cardiac Myocytes
Computer Simulation
Electrocardiography
In Vitro Techniques

Keywords

  • balanced ion channel-blocking drugs
  • CiPA
  • human induced pluripotent stem cell-derived ventricular cardiomyocytes
  • J-Tpeakc
  • torsade de pointes
  • torsade metric score

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting. / Strauss, David G.; Gintant, Gary; Li, Zhihua; Wu, Wendy; Blinova, Ksenia; Vicente, Jose; Turner, J. Rick; Sager, Philip T.

In: Therapeutic Innovation and Regulatory Science, 01.01.2018.

Research output: Contribution to journalArticle

Strauss, David G. ; Gintant, Gary ; Li, Zhihua ; Wu, Wendy ; Blinova, Ksenia ; Vicente, Jose ; Turner, J. Rick ; Sager, Philip T. / Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting. In: Therapeutic Innovation and Regulatory Science. 2018.
@article{9371254c2cd14e2496cd73892a396129,
title = "Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting",
abstract = "A Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA-sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring together scientists, clinicians, and regulators from multiple geographic regions to evaluate progress to date in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative, a new paradigm to evaluate proarrhythmic risk. Study reports from the 4 different components of the CiPA paradigm (ionic current studies, in silico modeling to generate a Torsade Metric Score, human induced pluripotent stem cell–derived ventricular cardiomyocytes, and clinical ECG assessments including J-Tpeakc) were presented and discussed. This paper provides a high-level summary of the CiPA data presented at the meeting.",
keywords = "balanced ion channel-blocking drugs, CiPA, human induced pluripotent stem cell-derived ventricular cardiomyocytes, J-Tpeakc, torsade de pointes, torsade metric score",
author = "Strauss, {David G.} and Gary Gintant and Zhihua Li and Wendy Wu and Ksenia Blinova and Jose Vicente and Turner, {J. Rick} and Sager, {Philip T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/2168479018795117",
language = "English (US)",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

AU - Strauss, David G.

AU - Gintant, Gary

AU - Li, Zhihua

AU - Wu, Wendy

AU - Blinova, Ksenia

AU - Vicente, Jose

AU - Turner, J. Rick

AU - Sager, Philip T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA-sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring together scientists, clinicians, and regulators from multiple geographic regions to evaluate progress to date in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative, a new paradigm to evaluate proarrhythmic risk. Study reports from the 4 different components of the CiPA paradigm (ionic current studies, in silico modeling to generate a Torsade Metric Score, human induced pluripotent stem cell–derived ventricular cardiomyocytes, and clinical ECG assessments including J-Tpeakc) were presented and discussed. This paper provides a high-level summary of the CiPA data presented at the meeting.

AB - A Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA-sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring together scientists, clinicians, and regulators from multiple geographic regions to evaluate progress to date in the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative, a new paradigm to evaluate proarrhythmic risk. Study reports from the 4 different components of the CiPA paradigm (ionic current studies, in silico modeling to generate a Torsade Metric Score, human induced pluripotent stem cell–derived ventricular cardiomyocytes, and clinical ECG assessments including J-Tpeakc) were presented and discussed. This paper provides a high-level summary of the CiPA data presented at the meeting.

KW - balanced ion channel-blocking drugs

KW - CiPA

KW - human induced pluripotent stem cell-derived ventricular cardiomyocytes

KW - J-Tpeakc

KW - torsade de pointes

KW - torsade metric score

UR - http://www.scopus.com/inward/record.url?scp=85053422768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053422768&partnerID=8YFLogxK

U2 - 10.1177/2168479018795117

DO - 10.1177/2168479018795117

M3 - Article

AN - SCOPUS:85053422768

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

ER -